Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Borqs Technologies

Imperial Petroleum

Transocean

How using volatility can help to profit with penny stocks The post Using Volatility to Make Money With Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Using Volatility to Make Money With Penny Stocks

Ginkgo Bioworks (NYSE: DNA ) stock has been making headlines left and right this month. The company has announced several new collaborations and acquisitions.

Can Acquisitions and Partnerships Take Ginkgo Bioworks (DNA) Stock Higher?

Carnival

Coinbase

FuboTV

Macy's

Palantir Technologies

Tilray Brands

This has been a rough year for stocks. Every time the market has tried to bounce, some fresh news has come out, triggering another selloff.

Ignore the Hype! These Are 7 of the Worst Stocks to Own Now

Program builds on the existing relationship between the partners following existing b-silk™ protein optimization project BOSTON , Oct. 20, 2022 /PRNewswire/ -- Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials. The first program in this collaboration aims to optimize the production efficiency of Bolt's Mylo™ material, a leather alternative made out of mycelium, the underground root-like system of fungi.

Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo™ Material

Zymergen

BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen.

Ginkgo Bioworks Completes Acquisition of Zymergen

Shopify

ARK Investment Management, the disruptive innovation firm founded by Catherine Wood (Trades, Portfolio), disclosed in a regulatory filing that its top five trades during the third quarter included boosts to its holdings in Shopify Inc. ( SHOP , Financial) and Gingko Bioworks ( DNA , Financial) and reductions of its holdings in Signify Health ( SGFY , Financial), Spotify Technology SA ( SPOT , Financial) and Stratasys Ltd. ( SSYS , Financial).

Cathie Wood's Firm Expands Shopify and Gingko Bioworks Holdings in 3rd Quarter

BOSTON , Oct. 17, 2022 /PRNewswire/ -- The Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence community, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and Draper, a nonprofit engineering innovation firm, today announced the completion of IARPA's Finding Engineering-Linked Indicators ( FELIX) program . The program was created to augment and improve current biodetection and biosurveillance capabilities.

IARPA, Ginkgo Bioworks and Draper Announce New Technologies to Detect Engineered DNA

It's an unforgettable day for Ginkgo Bioworks (NYSE: DNA ) as the company just disclosed a deal with pharmaceutical giant Merck (NYSE: MRK ). Together, the two companies hope to innovate pharmaceutical manufacturing processes through the use of enzyme technology.

What Is Going on With Ginkgo Bioworks (DNA) Stock Today?

Blue Apron

Canoo

Joby Aviation

Velodyne Lidar

5 penny stocks to watch this week. The post 5 Penny Stocks To Watch With Big News Is The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch With Big News Is The Stock Market Today

Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes BOSTON , Oct. 11, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Merck, known as MSD outside the United States and Canada, to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Through this collaboration, Ginkgo will leverage its extensive experience in cell engineering and enzyme design, as well as its capabilities in automated high throughput screening, manufacturing process development/optimization, bioinformatics and analytics to deliver optimal strains for expression of targeted biocatalysts.

Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing

Butterfly Network

Analysts expect these stocks to rise more than 100% once the rest of the market sees their underlying businesses in the same light.

2 Growth Stocks That Could Rocket 80% to 102% Higher, According to Wall Street

Source: Connect world / Shutterstock.com Ginkgo Bioworks (NYSE: DNA ) stock is in full focus today following ownership updates from three co-founders. The cell programming company has become a favorite of Ark Invest's Cathie Wood.

Co-founders Keep Buying Ginkgo Bioworks (DNA) Stock

Pursuing a horizontal platform strategy before the synthetic biology industry develops creates a risk of insufficient demand. Ginkgo's ability to capture downstream value is promoted, but companies like Synlogic and Cronos have not inspired confidence so far.

Ginkgo Bioworks: Business Model Uncertainty

These stocks have plenty of room to get a whole lot bigger in the years ahead.

2 Promising Growth Stocks Trading Under $10 a Share

BOSTON , Oct. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality.

Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy

BOSTON , Oct. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform. A fleet of Altar's automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo's Foundry to serve customers across food and beverage, biofuels, biomaterials, cosmetics, animal health and human health applications, among others.

Ginkgo Bioworks Acquires Adaptive Laboratory Evolution Company Altar

ARK Innovation ETF

Tesla

ARK Invest's strategy emphasizes the power of innovation, even if it's risky and pricey to invest in.

Want to Invest Like Cathie Wood? Use These 3 Principles.

This synbio stock was on the ARK funds' shopping list this week.

Why Shares of Ginkgo Bioworks Bounded Higher This Week

Acumen Pharmaceuticals

Alzamend Neuro

NeuroSense Therapeutics Ltd

Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes

The company has a near-term revenue driver in the form of the Joyn Bio deal and the fertilizer shortage. On the financial side, the balance sheet is in superb form given the stage of the company's development.

Ginkgo Bioworks: Promising Upside But Not Without Risks

Boeing

Core Scientific Inc

Carvana

Robinhood

Lucid Group

Norwegian Cruise Line

Peloton

Royal Caribbean Cruises

Rivian Automotive

Uber

WeWork

S&P 500 investors hate companies that lose money right now. So it's wise to know which companies are on the verge of losing obscene amounts so you don't end up holding the bag.

14 Ailing Companies Are About To Lose An Obscene Amount Of Money

Intellia Therapeutics

Verve Therapeutics

The founder and CEO of ARK Investment Management is buying up drugmaker stocks like they're going out of style.

Cathie Wood Goes Shopping for Biotech: 3 Stocks She Just Bought

NEW ORLEANS , Sept. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

ZYMERGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY

Teladoc

These stocks aren't for the faint of heart.

Cathie Wood Is Loading Up on These 3 Stocks: Should You?

It's possible the Oracle of Omaha would want to get on board for this stock, but not for at least a few years.

News for Ginkgo Bioworks Holdings Stock (DNA)